D is a high percentage of patients with childhood-onset schizophrenia were found to have TD or withdrawal dyskinesia was the most seriously, and this has improved over time. TD has the pr Morbid condition, disease severity and duration of exposure to antipsychotic Gemcitabine Gemzar medication taken in combination. In a meta-analysis of 10 longitudinal studies, Correll and Kane assessed the risk of TD with 1 year with second-generation antipsychotics in children and adolescents with exposure to move from a first generation antipsychotics associated minimal. P Pediatric patients has been again U risperidone, quetiapine or olanzapine. A total of only three new F TD w ll During a long-term treatment with atypical antipsychotics observed. In two of these F Lle, TD in the coming weeks after cessation of antipsychotic resolved St.
According to the authors, these results suggest that 1-year rates of TD with p Pediatric patients are relatively low. However, the present results due to low Stichprobengr E of studies with other agents Descr nkt That risperidone and of relatively low doses and short 17-AAG NSC330507 treatment times. So it can always be a potential h Higher risk for TD in boys with h Higher doses of neuroleptics for the whole or a liter Ngere exposure treatment. 3.5. Key Drowsiness or sedation, sedation is a side effect of h Frequently associated with antipsychotic medications. Learning of particular importance in the p Pediatric populations, such as young subjects need to be vigilant in the school, and f Rdern in their educational development.
The study analyzed antipsychotics show that the number to the sedation, drowsiness, perc Drowsiness or ranges of 2 3 for quetiapine, risperidone, and about 2 5 5 8 ben hurt by aripiprazole CONFIRMS. In open studies was key Drowsiness or fatigue were treated at 33% of patients with aripiprazole, 42, 69% of patients with ziprasidone, 25 80% treated with quetiapine, 29 risperidone, 89%, 44 94% reported with olanzapine and 46-90 % with clozapine. In general, little tolerance develops, in fact, in the follow-up studies were dizziness and sedation in only 2 6% of the F Lle reported. 3.6. Neuroleptic malignant syndrome, neuroleptic malignant syndrome is a rare but potentially associated t Dliche reaction with anti-psychotic drugs. This condition usually develops during the first weeks after the first exposure to antipsychotics, but it can develop at any time.
Neuroleptic malignant syndrome is primarily characterized by muscle rigidity with myonecrosis, a delirium Similar to catatonia and autonomic nervous system with hyperthermia, tachycardia and hypertension or hypotension. M Z Possible complications of the disease Select cardiac and respiratory arrest, aspiration pneumonia, myoglobinuric renal failure and disseminated intravascular coagulation. Catatonia and serotonin syndrome are important differences exclusion. Laboratory data have shown that increased Hte levels of creatine kinase and leukocytosiscan occur, but are not always in the malignant syndrome. In a contribution of 77 F Cases of neuroleptic malignant syndrome in patients aged 18 or less, the mortality rate was 9% and 20% have serious consequences for the F Lle reported. This syndrome has the confinement with atypical antipsychotics Lich risperidone, olanzapine, have been reported.